1.0¶¶Òõ»Æ°æÏÂÔØCommunications Department/author/cshl/rich600338<blockquote class="wp-embedded-content" data-secret="WPKCmC0sA0"><a href="/about-us/disease-funding-initiatives/pancreatic-cancer/">Pancreatic Cancer</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="/about-us/disease-funding-initiatives/pancreatic-cancer/embed/#?secret=WPKCmC0sA0" width="600" height="338" title="“Pancreatic Cancer” — ¶¶Òõ»Æ°æÏÂÔØ" data-secret="WPKCmC0sA0" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); /* ]]> */ </script> CSHL has several researchers working on pancreatic cancer. David Tuveson, Professor, directs the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL (see below). Greg Hannon, Professor and HHMI Investigator, uses sophisticated technologies to better understand the biology of pancreatic cancer and to uncover new therapeutic targets. Mikala Egeblad, Assistant Professor, has developed a novel imaging system to better characterize the complex interactions between pancreatic tumor cells and the surrounding microenvironment, which has implications for improving therapeutic options for pancreatic cancer.